<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>348</serviceExecutionTime><Drug id="11561"><DrugName>TF inhibitors (antiviral), Tularik/Merck &amp; Co</DrugName><DrugSynonyms><Name><Value>TF inhibitors (antiviral), Tularik/Merck &amp; Co</Value></Name></DrugSynonyms><CompanyOriginator id="20449">Tularik Inc</CompanyOriginator><CompaniesSecondary><Company id="18077">Merck &amp; Co Inc</Company><Company id="20449">Tularik Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="20449" type="Company"><TargetEntity id="4295915224" type="organizationId">Tularik Inc</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="157" type="ciIndication"><TargetEntity id="B00" type="ICD10"></TargetEntity><TargetEntity id="054" type="ICD9"></TargetEntity><TargetEntity id="10019948" type="MEDDRA"></TargetEntity><TargetEntity id="D006561" type="MeSH"></TargetEntity><TargetEntity id="-1360288263" type="omicsDisease"></TargetEntity><TargetEntity id="858" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="287" type="ciIndication"><TargetEntity id="10061603" type="MEDDRA"></TargetEntity><TargetEntity id="D018357" type="MeSH"></TargetEntity><TargetEntity id="-1462311917" type="omicsDisease"></TargetEntity><TargetEntity id="866" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3299" type="ciIndication"><TargetEntity id="10015108" type="MEDDRA"></TargetEntity><TargetEntity id="D020031" type="MeSH"></TargetEntity><TargetEntity id="-966509320" type="omicsDisease"></TargetEntity><TargetEntity id="857" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="396" type="ciIndication"><TargetEntity id="D030361" type="MeSH"></TargetEntity><TargetEntity id="-774172916" type="omicsDisease"></TargetEntity><TargetEntity id="865" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="89" type="ciIndication"><TargetEntity id="B25" type="ICD10"></TargetEntity><TargetEntity id="10011831" type="MEDDRA"></TargetEntity><TargetEntity id="D003586" type="MeSH"></TargetEntity><TargetEntity id="-1997766704" type="omicsDisease"></TargetEntity><TargetEntity id="856" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication><Indication id="157">Herpes simplex virus infection</Indication><Indication id="158">HIV infection</Indication><Indication id="287">Respiratory syncytial virus infection</Indication><Indication id="3299">Epstein Barr virus infection</Indication><Indication id="396">Papillomavirus infection</Indication><Indication id="89">Cytomegalovirus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T07:11:15.000Z</LastModificationDate><ChangeDateLast>2013-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Tularik and &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt; were involved in a collaboration to discover and develop small molecule inhibitors of viral replication [&lt;ulink linkID="195065" linkType="reference"&gt;195065&lt;/ulink&gt;], [&lt;ulink linkID="229798" linkType="reference"&gt;229798&lt;/ulink&gt;]. However, the agreement was terminated in March 1999 [&lt;ulink linkID="355753" linkType="reference"&gt;355753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 1998, some compounds had been shown to inhibit the UL5 helicase-primase protein of HSV at a concentration of 5 to 10 microM [&lt;ulink linkID="286280" linkType="reference"&gt;286280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1994, the companies entered into an agreement covering human immunodeficiency virus (HIV), cytomegalovirus (CMV), respiratory syncytial virus (RSV), herpes simplex virus (HSV), Epstein Barr virus (EBV) and human papillomavirus (HPV). Under the terms of the agreement, Merck had exclusive worldwide rights to any products developed to treat HSV, HPV or HIV, while Tularik retained rights to CMV, RSV and EBV [&lt;ulink linkID="195065" linkType="reference"&gt;195065&lt;/ulink&gt;], [&lt;ulink linkID="286280" linkType="reference"&gt;286280&lt;/ulink&gt;]. The agreement was extended in January 1997, to run for up to three more years. Under the revised agreement, the specific disease targets to be addressed included HIV and hepatitis C virus (HCV). Merck was granted worldwide rights to any products developed for HCV [&lt;ulink linkID="229798" linkType="reference"&gt;229798&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1997, Tularik announced that it had been issued with the patent US-05585239, which covers high throughput drug screening assays for drugs which interfere with HSV-specific transcription [&lt;ulink linkID="230925" linkType="reference"&gt;230925&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3299">Epstein Barr virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="396">Papillomavirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3299">Epstein Barr virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="89">Cytomegalovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="157">Herpes simplex virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="396">Papillomavirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="157">Herpes simplex virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="89">Cytomegalovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-03-01T00:00:00.000Z</StatusDate><Source id="355753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3299">Epstein Barr virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-16T00:00:00.000Z</StatusDate><Source id="229798" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="157">Herpes simplex virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20449">Tularik Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="89">Cytomegalovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3299">Epstein Barr virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate><Source id="229798" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="89">Cytomegalovirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate><Source id="229798" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="157">Herpes simplex virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate><Source id="229798" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-16T00:00:00.000Z</StatusDate><Source id="229798" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-01-01T00:00:00.000Z</StatusDate><Source id="229798" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc(cc1)S(=O)(=O)NN2C(=O)/C(=C\c3ccc(c(c3)Cl)Cl)/SC2=S</Smiles></StructureSmiles><Deals><Deal id="116478" title="Merck and Tularik to codevelop antiviral TF inhibitors worldwide       "></Deal></Deals><PatentFamilies><PatentFamily id="1534372" number="WO-09413315" title="A novel eukaryotic transcription protein: host cell factor."></PatentFamily><PatentFamily id="1976744" number="WO-09942455" title="Antiviral agents."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cold Spring Harbor Laboratory" id="15518"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>